問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳冠亨

Recruiting

List

29Cases

2021-01-04 - 2026-04-30

Phase III

Active
A Phase 3 Study of CG0070 in Patients with Non-Muscular Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG)

  • Condition/Disease

    This is a Phase 3, open-label, trial designed to evaluate CG0070 in patients with high-grade CIS of the bladder unresponsive to Bacillus Calmette-Guerin (BCG).

  • Test Drug

    CG0070 DDM

Participate Sites
4Sites

Recruiting4Sites

2023-03-20 - 2030-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2019-07-22 - 2026-12-29

Phase III

Active
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy

  • Condition/Disease

    Advanced Prostate Cancer

  • Test Drug

    Apalutamide (JNJ-56021927)

Participate Sites
7Sites

Recruiting7Sites

2021-01-01 - 2029-10-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2019-01-01 - 2027-05-27

Phase III

Active
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer

  • Condition/Disease

    Metastatic prostate cancer

  • Test Drug

    Niraparib

Participate Sites
9Sites

Recruiting8Sites

Terminated1Sites

吳文正
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Urology

2018-09-26 - 2022-05-18

Phase III

Active
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination With Standard of Care Chemotherapy and Durvalumab in Combination With Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients With Unresectable Locally Advanced or Metastatic Urothelial Cancer.

  • Condition/Disease

    Locally Advanced or Metastatic Urothelial Cancer

  • Test Drug

    Durvalumab (MEDI4736)

Participate Sites
7Sites

Recruiting6Sites

蘇柏榮
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2023-10-01 - 2031-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2018-09-28 - 2026-12-31

Phase III

Active
A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer

  • Condition/Disease

    Muscle-Invasive Bladder Cancer

  • Test Drug

    Durvalumab

Participate Sites
8Sites

Recruiting6Sites

Terminated1Sites

2021-08-01 - 2029-12-31

Phase III

Active
A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)

  • Condition/Disease

    Muscle Invasive Bladder Cancer

  • Test Drug

    注射劑 注射劑 注射劑

Participate Sites
5Sites

Recruiting5Sites

2023-10-31 - 2035-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB